Anika Therapeutics
ANIK
131 hedge funds and large institutions have $560M invested in Anika Therapeutics in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 39 increasing their positions, 52 reducing their positions, and 13 closing their positions.
89% more call options, than puts
Call options by funds: $498K | Put options by funds: $264K
0.15% less ownership
Funds ownership: 91.36% → 91.21% (-0.15%)
2% less capital invested
Capital invested by funds: $569M → $560M (-$9.58M)
6% less funds holding
Funds holding: 139 → 131 (-8)
25% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 52
54% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$10.7M |
| 2 |
TI
Trigran Investments
Northbrook,
Illinois
|
+$9.98M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$3.67M |
| 4 |
CM
Capital Management
Glen Allen,
Virginia
|
+$790K |
| 5 |
SG Americas Securities
New York
|
+$712K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baird Financial Group
Milwaukee,
Wisconsin
|
-$5.85M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.58M |
| 3 |
PGM
Parian Global Management
Pound Ridge,
New York
|
-$2.92M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
-$2.17M |
| 5 |
Two Sigma Investments
New York
|
-$2.07M |
ANIK Hedge Fund Activity: Q3 2021 in Review
131 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q3 2021, worth a combined $560M — down 1.7% from $569M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ANIK and 6 opened new positions — a net loss of 7 holders — while 52 trimmed existing stakes and 39 added.
The largest buyer was Janus Henderson Group, adding an estimated $10.7M. The largest seller was Baird Financial Group, exiting entirely with an estimated $5.85M sold.
- 131 institutional investors held Anika Therapeutics (ANIK) as of Q3 2021, down from 139 in Q2 2021.
- Funds reported $560M of Anika Therapeutics stock for Q3 2021, down 1.7% quarter-over-quarter.
- 6 funds opened new Anika Therapeutics positions in Q3 2021 and 13 closed out, a net change of -7 holders.
- The largest Anika Therapeutics buyer in Q3 2021 was Janus Henderson Group, an estimated $10.7M added.
- The largest Anika Therapeutics seller in Q3 2021 was Baird Financial Group, an estimated $5.85M sold.
Based on aggregated 13F filings for Q3 2021.